Is Processa Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: PCSA) stock is to Buy PCSA stock.
Out of 1 analyst, 0 (0%) are recommending PCSA as a Strong Buy, 1 (100%) are recommending PCSA as a Buy, 0 (0%) are recommending PCSA as a Hold, 0 (0%) are recommending PCSA as a Sell, and 0 (0%) are recommending PCSA as a Strong Sell.
What is PCSA's earnings growth forecast for 2025-2025?
(NASDAQ: PCSA) Processa Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Processa Pharmaceuticals's earnings in 2025 is -$11,850,118.
In 2025, PCSA is forecast to generate -$11,381,558 in earnings, with the lowest earnings forecast at -$11,381,558 and the highest earnings forecast at -$11,381,558.
What is PCSA's forecast return on equity (ROE) for 2025-2025?
(NASDAQ: PCSA) forecast ROE is -671.01%, which is considered weak.
What is PCSA's Price Target?
According to 1 Wall Street analyst that have issued a 1 year PCSA price target, the average PCSA price target is $6.00, with the highest PCSA stock price forecast at $6.00 and the lowest PCSA stock price forecast at $6.00.
The Wall Street analyst predicted that Processa Pharmaceuticals's share price could reach $6.00 by Dec 5, 2025. The average Processa Pharmaceuticals stock price prediction forecasts a potential upside of 2,627.27% from the current PCSA share price of $0.22.
What is PCSA's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: PCSA) Processa Pharmaceuticals's current Earnings Per Share (EPS) is -$3.87. In 2025, PCSA's EPS is forecast to hit -$2.16 (min: -$2.16, max: -$2.16).
What is PCSA's forecast return on assets (ROA) for 2025-2025?
(NASDAQ: PCSA) forecast ROA is -352.45%, which is lower than the forecast US Biotechnology industry average of 103.31%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.